TP53 and neoplasm: Specific exclusion of borderline tumours, with this study only investigating LGSOC with definitive stromal invasion, nuclear WT1 expression and wild-type p53 immunoprofile, is also a major strength, alongside the extensive follow-up period (median 13 years).